Hongmei J. Zhang

China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

First-line Aumolertinib (EGFR tyrosine kinase inhibitor) plus apatinib (VEGFR inhibitor) versus aumolertinib in EGFR-mutant non-small cell lung cancer patients: a randomized, multicenter, phase II trial.

First-line Aumolertinib (EGFR tyrosine kinase inhibitor) plus apatinib (VEGFR inhibitor) versus aumolertinib in EGFR-mutant non-small cell lung cancer patients: a randomized, multicenter, phase II trial.

Journal: Signal transduction and targeted therapy

Published: June 06, 2025

Clinical and molecular characteristics of periampullary carcinoma based on pathological subtypes.

Clinical and molecular characteristics of periampullary carcinoma based on pathological subtypes.

Journal: Journal of gastrointestinal oncology

Published: January 07, 2025

Multifocal primary Rosai-Dorfman disease of trachea: report of a case

Multifocal primary Rosai-Dorfman disease of trachea: report of a case

Journal: Zhonghua bing li xue za zhi = Chinese journal of pathology

Published: October 31, 2024

Camrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the CameL randomized phase 3 study.

Camrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the CameL randomized phase 3 study.

Journal: Journal for immunotherapy of cancer

Published: October 10, 2024

Correction: Zeng et al. Research on Aviation Safety Prediction Based on Variable Selection and LSTM. Sensors 2023, 23, 41.

Correction: Zeng et al. Research on Aviation Safety Prediction Based on Variable Selection and LSTM. Sensors 2023, 23, 41.

Journal: Sensors (Basel, Switzerland)

Published: August 30, 2024

Rechallenge of immune checkpoint inhibitors in advanced non-small cell lung cancer.

Rechallenge of immune checkpoint inhibitors in advanced non-small cell lung cancer.

Journal: Thoracic cancer

Published: November 27, 2023

Clinical definition of secondary resistance to immunotherapy in non-small cell lung cancer.

Clinical definition of secondary resistance to immunotherapy in non-small cell lung cancer.

Journal: Thoracic cancer

Published: October 25, 2023

Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer.

Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: August 30, 2023

Hyperthermic intrathoracic/intraperitoneal chemotherapy versus conventional intrapleural/intraperitoneal chemotherapy for the malignant effusion: a multi-center randomized clinical trial.

Hyperthermic intrathoracic/intraperitoneal chemotherapy versus conventional intrapleural/intraperitoneal chemotherapy for the malignant effusion: a multi-center randomized clinical trial.

Journal: International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group

Published: August 13, 2023

Chinese Medical Association consensus for standardized diagnosis and treatment of pancreatic neuroendocrine neoplasms.

Chinese Medical Association consensus for standardized diagnosis and treatment of pancreatic neuroendocrine neoplasms.

Journal: Chinese medical journal

Published: May 17, 2023

Reconstructing avascular necrotic femoral head through a bioactive β-TCP system: From design to application.

Reconstructing avascular necrotic femoral head through a bioactive β-TCP system: From design to application.

Journal: Bioactive materials

Published: March 09, 2023

Chinese expert consensus recommendations for the administration of immune checkpoint inhibitors to special cancer patient populations.

Chinese expert consensus recommendations for the administration of immune checkpoint inhibitors to special cancer patient populations.

Journal: Therapeutic advances in medical oncology

Published: December 09, 2022

Showing 1-12 of 14

Last Updated: 09/26/2026